Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections

被引:0
|
作者
Taubert, Max [1 ]
Lueckermann, Mark [2 ]
Vente, Andreas [2 ]
Dalhoff, Axel [3 ]
Fuhr, Uwe [1 ]
机构
[1] Univ Hosp Cologne, Clin Pharmacol Unit, Dept Pharmacol, Cologne, Germany
[2] MerLion Pharmaceut GmbH, Berlin, Germany
[3] Christian Albrechts Univ Kiel, Inst Infect Med, Kiel, Germany
关键词
clinical trials; finafloxacin; pharmacodynamics; population pharmacokinetics; urinary tract infection; ECONOMIC-EVALUATION; INVITRO ACTIVITY; FLUOROQUINOLONE; CIPROFLOXACIN; THERAPY; PH; ACETAMINOPHEN; COMPLETENESS; ASPIRIN; HEIGHT;
D O I
10.1128/AAC.02328-17
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Finafloxacin is a novel fluoroquinolone with increased antibacterial activity at acidic pH and reduced susceptibility to several resistance mechanisms. A phase II study revealed a good efficacy/safety profile in patients with complicated urinary tract infections (cUTIs), while the pharmacokinetics was characterized by highly variable concentration-versus-time profiles, suggesting the need for an elaborated pharmacokinetic model. Data from three clinical trials were evaluated: 127 healthy volunteers were dosed orally (n = 77) or intravenously (n = 50), and 139 patients with cUTI received finafloxacin intravenously. Plasma (2,824 samples from volunteers and 414 samples from patients) and urine (496 samples from volunteers and 135 samples patients) concentrations were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). NONMEM was used to build a population pharmacokinetic model, and pharmacokinetic/pharmacodynamic relationships were investigated via simulations and logistic regression. A two-compartment model with first-order elimination described the data best (central volume of distribution [V-c] and peripheral volume of distribution [V-p] of 47 liters [20%] and 43 liters [67%], respectively, and elimination clearance and intercompartmental clearance of 21 liters/h [54%] and 2.8 liters/h [57%], respectively [median bootstrap estimates {coefficients of variation}]). V-c increased with body surface area, and clearance was reduced in patients (-29%). Oral absorption was described best by parallel first-and zero-order processes (bioavailability of 75%). No pharmacodynamic surrogate parameter of clinical/microbiological outcome could be identified, which depended exclusively on the MIC of the causative pathogens. Despite the interindividual variability, the present data set does not support covariate-based dose adjustments. Based on the favorable safety and efficacy data, the clinical relevance of the observed variability appears to be limited.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Population pharmacokinetics of tigecycline in healthy volunteers
    Van Wart, S. A.
    Cirincione, B. B.
    Ludwig, E. A.
    Meagher, A. K.
    Korth-Bradley, J. M.
    Owen, J. S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (06): : 727 - 737
  • [32] Population pharmacokinetics of fentanyl in healthy volunteers
    Ariano, RE
    Duke, PC
    Sitar, DS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (07): : 757 - 763
  • [33] Population pharmacokinetics of alfentanil in healthy volunteers and surgical patients.
    Ariano, RE
    Duke, P
    Sitar, DS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P13 - P13
  • [34] Population pharmacokinetics of morphine in healthy volunteers and utility for patients.
    Ariano, RE
    Duke, PC
    Sitar, DS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P43 - P43
  • [35] Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies
    Connarn, Jamie N.
    Hwang, Renfang
    Gao, Yue
    Palmisano, Maria
    Chen, Nianhang
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (05): : 465 - 473
  • [36] PHARMACOKINETICS AND EFFICACY OF SISOMICIN IN PATIENTS WITH URINARY-TRACT INFECTIONS
    WEISSBACH, L
    GILLISSEN, J
    LODE, H
    INFECTION, 1979, 7 : S288 - S289
  • [37] Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections
    Samara, Emil
    Shaw, Jeng-Pyng
    Barriere, Steven L.
    Wong, Shekman L.
    Worboys, Philip
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 2067 - 2073
  • [38] The prevalence of incontinence in a population of patients with urinary tract infections
    Grootemaat, M.
    Bolster, J.
    van Uhm, J.
    Noordzij, A.
    Elzevier, H.
    van der Veen, H.
    Schellart, R.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2022, 33 (SUPPL 1) : S82 - S82
  • [39] The additional value of blood cultures in patients with complicated urinary tract infections
    Spoorenberg, V.
    Prins, J. M.
    Opmeer, B. C.
    de Reijke, T. M.
    Hulscher, M. E. J. L.
    Geerlings, S. E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (08) : O476 - O479
  • [40] Cefepime/Enmetazobactam for Complicated Urinary Tract Infections
    Advani, Sonali D.
    Claeys, Kimberly
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (13): : 1299 - 1301